Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.
about
Oxidized phospholipids and lipoprotein-associated phospholipase A2 as important determinants of Lp(a) functionality and pathophysiological roleImaging Atherosclerosis.Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complicationsThe year in cardiology 2014: acute coronary syndromesThe role of T and B cells in human atherosclerosis and atherothrombosisLp-PLA2 Antagonizes Left Ventricular Healing After Myocardial Infarction by Impairing the Appearance of Reparative MacrophagesLeveraging human genetics to guide drug target discovery.Genetic invalidation of Lp-PLA2 as a therapeutic target: Large-scale study of five functional Lp-PLA2-lowering alleles.The Therapeutic Potential of Anti-Inflammatory Exerkines in the Treatment of AtherosclerosisMitochondrial Reactive Oxygen Species Mediate Lysophosphatidylcholine-Induced Endothelial Cell Activation.Genetics of coronary artery disease: discovery, biology and clinical translation.Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese populationTreating coronary disease and the impact of endothelial dysfunction.STABILITY and SOLID-TIMI 52: Lipoprotein associated phospholipase A2 (Lp-PLA2) as a biomarker or risk factor for cardiovascular diseases.Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trialColchicine Acutely Suppresses Local Cardiac Production of Inflammatory Cytokines in Patients With an Acute Coronary SyndromeAssociation of Lp-PLA2-A and early recurrence of vascular events after TIA and minor stroke.Lipoprotein associated phospholipase A2 activity, apolipoprotein C3 loss-of-function variants and cardiovascular disease: The Atherosclerosis Risk In Communities StudySurprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis.Neutrophil effector responses are suppressed by secretory phospholipase A2 modified HDL.Lipoprotein-Associated Phospholipase A2 and Incident Peripheral Arterial Disease in Older Adults: The Cardiovascular Health Study.Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease.Qing-Xin-Jie-Yu Granules in addition to conventional treatment for patients with stable coronary artery disease (QUEST Trial): study protocol for a randomized controlled trialSerum oxidized low-density lipoprotein decreases in response to statin therapy and relates independently to reductions in coronary plaque in patients with HIV.A phenome-wide association study of a lipoprotein-associated phospholipase A2 loss-of-function variant in 90 000 Chinese adults.Effect of intensive insulin treatment on plasma levels of lipoprotein-associated phospholipase A2 and secretory phospholipase A2 in patients with newly diagnosed type 2 diabetesA previously unreported impact of a PLA2G7 gene polymorphism on the plasma levels of lipoprotein-associated phospholipase A2 activity and mass.Systematic Evaluation of Pleiotropy Identifies 6 Further Loci Associated With Coronary Artery Disease.Exploring the plasmatic platelet-activating factor acetylhydrolase activity in patients with anti-phospholipid antibodies.Why do statins reduce cardiovascular disease more than other lipid modulating therapies?Role of vascular inflammation in coronary artery disease: potential of anti-inflammatory drugs in the prevention of atherothrombosis. Inflammation and anti-inflammatory drugs in coronary artery disease.Darapladib for the treatment of cardiovascular disease.The year in cardiology 2014: coronary intervention.MethotrexaTE THerapy in ST-Segment Elevation MYocardial InfarctionS.Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial.Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology.The vulnerable atherosclerotic plaque: in vivo identification and potential therapeutic avenues.The role of inflammatory biomarkers in developing targeted cardiovascular therapies: lessons from the cardiovascular inflammation reduction trials.Investigational new drugs for the treatment of acute coronary syndrome.Intracoronary imaging of coronary atherosclerosis: validation for diagnosis, prognosis and treatment.
P2860
Q26747100-8F88F9FB-FA35-4209-8F01-A034DA7F53D2Q26764836-EA6E51BE-57A1-4CD3-B587-BB83457C7223Q26777871-905EF9DE-7586-49CF-8684-384F543359EBQ26865907-9107FC86-F557-42B0-B914-E158A6BCF61FQ27000791-C3EDDE65-01D7-4605-90F8-8873BAB94A25Q28388609-854B4102-6200-4137-887B-D833EA5D5AC6Q30245007-E5CAECDD-C2EF-4CAB-868F-C8E5BB501F0CQ33768940-B4C2AC25-2776-4F40-8760-E012654BC2E8Q33838927-E7DB7220-52A5-4DA1-B908-579A01481B28Q34524163-E124FBDE-7862-4181-9882-AF9F3F760D27Q34553141-D9A40C87-6743-4C72-B061-CEE95CDB823AQ35169770-193A960D-2B8A-441B-9EDA-F4EF5DA608EDQ35196366-8EF3E55C-DFB5-48D0-B279-CA21A0DEB40AQ35217973-A30C2B5E-6ED1-49EE-BFE4-5775F022A7A7Q36019971-068B7FA0-50E2-4170-B52C-9321548A7DB4Q36141649-8CA785BA-0722-46B5-B19E-D6F2AEAA2E98Q36272238-31385D93-D0CB-4DC3-9C59-22F980F59990Q36517373-237D56CF-0DE6-4003-AAA9-A8AB2B9A089DQ36602779-9138CAC6-4D2B-42F2-B8E1-A77B06F807E6Q36681188-C1C8B9D0-8F88-492A-B498-25F61487204DQ36730558-4796C6E7-9946-4436-9035-71C9767B00BDQ37076194-329D5C5B-D746-4E7F-BBAA-E76B63622DBEQ37258254-6CD15DB3-D2B0-497E-9759-53A017D88FA6Q37294964-6CDE9C8A-4B94-4A32-A244-70BF22FA683BQ37401167-1F856A3B-230B-4232-BFA1-1B6B606A8474Q37431606-801F438F-15EE-437B-8F64-E45E7B1056F8Q37460258-8278F30A-5576-4BF6-ABBC-AC4C0656FEE6Q37648324-824D356B-048A-4E93-839F-1453936CFC3CQ37720776-75B53230-4475-4E1E-ADE3-5174015EBD3EQ38253965-F11B08E3-C4B9-4A02-8EED-919680CCD683Q38265002-8A915178-2FDF-4627-9BCD-F87E475E2308Q38293061-637BCDA5-98C1-4FDC-8470-5423B8E1F6E3Q38307432-C20FC69C-B7B8-4899-B9A7-21756BF956A4Q38379218-CA87894C-75AB-4EEA-9F58-1E26ADDF6444Q38382538-F0F2F9A7-691F-4E7A-87F6-75A96618FF8FQ38528288-F51B1C69-13A4-42C5-9EAE-0F18FCE97FC0Q38585451-29065D7E-30C2-4174-937D-F157759DC1A8Q38593722-C8C0CB79-7AB9-4432-9109-ECCD15A21FA6Q38594609-37FAEB6E-F83B-4E84-AC1F-6E925AA57F9DQ38665986-82B4CE4C-0E8F-4EF4-80DB-19F0C24FEC9E
P2860
Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Effect of darapladib on major ...... 52 randomized clinical trial.
@en
type
label
Effect of darapladib on major ...... 52 randomized clinical trial.
@en
altLabel
Effect of darapladib on major ...... I 52 randomized clinical trial
@en
prefLabel
Effect of darapladib on major ...... 52 randomized clinical trial.
@en
P2093
P50
P356
P1476
Effect of darapladib on major ...... 52 randomized clinical trial.
@en
P2093
Christopher P Cannon
David F Watson
Dylan L Steen
Elizabeth Tarka
Harvey D White
Jennifer B Shannon
KyungAh Im
Marc P Bonaca
Mary Ann Lukas
Michelle L O'Donoghue
P304
P356
10.1001/JAMA.2014.11061
P407
P577
2014-09-01T00:00:00Z